TMS vs. SPRAVATO: compare how each depression treatment works, potential benefits, side effects, and who may be a candidate.
Transcranial Magnetic Stimulation, commonly called TMS, is a non-invasive treatment that uses magnetic pulses to stimulate targeted areas of the brain.
A treatment coil is positioned against the scalp. The device then delivers brief magnetic pulses that pass through the skull and induce electrical currents in targeted brain tissue. The goal is to influence neural activity in brain regions involved in mood regulation.
Unlike medication-based treatment, TMS does not require a drug to circulate throughout the body. It also does not require surgery or general anesthesia.
TMS is usually delivered as a course of repeated outpatient sessions. The exact protocol and treatment schedule depend on the TMS system being used, the condition being treated, and the patient’s individual treatment plan.
For depression, TMS may be considered when someone has not achieved adequate improvement with previous treatment.
That distinction matters. TMS is not simply a replacement for antidepressants or psychotherapy. It can be considered as another treatment option within a broader mental healthcare plan.
SPRAVATO is the brand name for esketamine nasal spray.
Esketamine is a prescription medication that acts on the brain’s glutamate system as an NMDA receptor antagonist. The FDA-approved labeling includes treatment-resistant depression in adults, used in conjunction with an oral antidepressant.
It is also indicated for depressive symptoms in adults with major depressive disorder accompanied by acute suicidal ideation or behavior, in conjunction with an oral antidepressant.
Because SPRAVATO can cause sedation, dissociation, increases in blood pressure, and other temporary effects, it must be administered under appropriate healthcare supervision. Patients are monitored after treatment rather than simply taking the medication and leaving immediately.
The biggest difference between TMS and SPRAVATO is the mechanism of treatment.
TMS uses magnetic energy to influence activity in targeted areas of the brain.
The magnetic pulses are delivered through a treatment coil placed against the scalp. For depression, TMS protocols target brain regions associated with mood regulation. Repeated treatment sessions are intended to produce therapeutic changes in neural activity and connectivity over time.
The treatment is non-invasive, and the patient remains awake during the procedure.
SPRAVATO works pharmacologically rather than through external magnetic stimulation.
Its active ingredient, esketamine, is a non-competitive NMDA receptor antagonist that affects the glutamate system in the brain. It is used alongside an oral antidepressant for its FDA-approved depression indications.
Because it is a medication that can temporarily affect alertness, perception, and blood pressure, SPRAVATO treatment requires monitoring by healthcare professionals.
Although both may be discussed when depression has not improved adequately with previous treatment, the actual treatment experience can be very different.
| Factor | TMS Therapy | SPRAVATO |
|---|---|---|
| Treatment type | Non-invasive brain stimulation | Prescription medication |
| Administration | Magnetic stimulation through a treatment coil | Nasal spray |
| Medication involved | No medication is administered during TMS | Esketamine |
| Anesthesia | Not required | Not required |
| Patient remains awake | Yes | Generally awake, but temporary sedation or altered perception can occur |
| Monitoring | Treatment is supervised | Post-dose monitoring is required |
| Driving afterward | Often possible, depending on provider guidance | Patients should not drive until the next day after a restful sleep |
| Treatment course | Usually multiple sessions | Scheduled doses with a monitoring period |
| Common treatment-related concerns | Scalp discomfort, headache | Sedation, dissociation, dizziness, nausea, increased blood pressure |
The table gives you the broad picture, but it shouldn’t be used as a substitute for medical guidance. Treatment protocols and eligibility can vary.
This is one of the most common questions people have when researching TMS vs. SPRAVATO.
SPRAVATO has demonstrated antidepressant effects in clinical studies, and some people may experience improvement relatively quickly. However, response varies from person to person, and rapid symptom improvement should not be interpreted as a guarantee of long-term remission.
TMS generally works through a course of repeated stimulation rather than a single treatment. Its effects are assessed over time as treatment progresses. So, if speed is important to you, tell your provider.
That conversation becomes especially important when depression is severe, symptoms are worsening, or there are concerns about suicidal thoughts or behavior. SPRAVATO’s FDA labeling specifically notes that it has not been demonstrated to prevent suicide or reduce suicidal ideation or behavior, and it does not replace hospitalization when hospitalization is clinically necessary.
Every treatment has potential risks. The important thing is understanding what those risks look like and whether they matter in your particular situation.
TMS is generally well tolerated, but some people experience:
There is also a rare risk of seizure. Your provider should review your medical history, medications, and any relevant neurological conditions before treatment. FDA guidance for rTMS devices emphasizes screening for contraindications and precautions, including certain implanted devices and neurological conditions.
SPRAVATO can cause:
Because of these potential effects, SPRAVATO is administered under supervision with post-treatment monitoring. The FDA prescribing information also carries important warnings concerning sedation, dissociation, respiratory depression, abuse and misuse, and other risks.
The difference isn’t simply that one treatment has “side effects” and the other doesn’t. The type, timing, and monitoring requirements are different.
For many patients, the practical experience of TMS is straightforward.
You remain seated while the treatment coil is positioned against your scalp. During stimulation, you may hear clicking sounds and feel tapping or pulsing sensations. You remain awake and can communicate with the treatment team.
TMS is usually delivered through repeated appointments rather than one procedure. NeuroStar, for example, describes its treatment as an outpatient, non-drug approach for depression.
The number and frequency of sessions depend on the treatment protocol and individual circumstances.
SPRAVATO is administered as a nasal spray in a certified healthcare setting.
After administration, you remain at the facility while healthcare professionals monitor you. This monitoring is important because esketamine can temporarily affect alertness, perception, blood pressure, and coordination.
You should plan around the appointment accordingly. Unlike a typical TMS session, you should not expect to simply finish SPRAVATO administration and immediately return to driving, work, or other normal activities.
TMS may be appropriate for some people with depression who have not received enough benefit from previous treatments.
Your provider may consider:
NeuroStar is FDA-cleared for major depressive disorder and has additional cleared indications, including OCD and decreasing anxiety symptoms associated with major depressive disorder. Its current labeling also includes an adolescent depression indication for ages 15–21.
That does not mean everyone with depression is automatically a candidate. A clinical evaluation is still necessary.
SPRAVATO is FDA-approved for specific depression indications in adults.
For treatment-resistant depression, the FDA indication is for adults with inadequate response to at least two antidepressant treatments of adequate dose and duration during the current depressive episode, with SPRAVATO used alongside an oral antidepressant.
Eligibility also involves safety considerations. Your healthcare provider may need to review your blood pressure, medical history, medications, substance-use history, and other factors before determining whether SPRAVATO is appropriate.
The treatment is subject to a restricted safety program because of its potential risks.
This is where the comparison becomes personal.
These are not rules for deciding treatment. They are starting points for a conversation with a qualified provider.
Before choosing between TMS and SPRAVATO, consider asking:
Good treatment decisions are rarely about finding a magic option. They’re about finding a reasonable next step and monitoring how your mental health responds.
Not really. TMS and SPRAVATO work differently and have different treatment schedules, risks, and eligibility requirements. The appropriate option depends on your individual clinical situation.
Treatment combinations should only be considered under the direction of qualified healthcare professionals. Your provider can determine whether combining treatments is appropriate based on your medical history and current treatment plan.
TMS can cause scalp discomfort, tapping sensations, or headaches in some people. The experience varies, and your provider can adjust treatment parameters when appropriate.
It can. SPRAVATO may temporarily cause sedation, dizziness, dissociation, or changes in perception. This is one reason treatment must be administered under healthcare supervision and followed by monitoring.
TMS is generally delivered as a series of treatment sessions. The exact number, frequency, and duration depend on the treatment protocol and your individual treatment plan.
Patients should not drive, operate machinery, or make important decisions until the following day after a restful night’s sleep, according to the FDA prescribing information. Your treatment provider will give you specific instructions.
No. SPRAVATO contains esketamine, which is a specific form of ketamine-related medication. FDA-approved esketamine nasal spray and ketamine treatments are not interchangeable, and ketamine itself is not FDA-approved for treating psychiatric disorders.
Choosing between TMS and SPRAVATO is not about finding the treatment that sounds most powerful on paper. It’s about finding the treatment that makes sense for you.
TMS offers a non-drug approach that uses targeted magnetic stimulation, while SPRAVATO offers a medication-based option that requires supervised administration and monitoring. Both have potential benefits and risks, and both require proper clinical evaluation.
If depression continues to interfere with your daily life despite previous treatment, you don’t have to figure out the next step alone.
